All AbMole products are for research use only, cannot be used for human consumption.
GSK256066 is a selective phosphodiesterase 4 (PDE4)inhibitor with an IC50 of 3.2 pM. Oral phosphodiesterase (PDE)4 inhibitors have demonstrated clinical efficacy in chronic obstructive pulmonary disease and asthma. Preclinical andclinical investigation of inhaled PDE4 inhibitors is ongoing. GSK256066 may have an improved therapeutic index compared with oral PDE4 inhibitors, e.g., cilomilast and roflumilast.GSK256066 demonstrates potent and long-lasting anti-inflammatory effects in animal models of pulmonary inflammation and does not induce emetic episodes in ferrets. GSK256066 has potential as an inhaled therapeutic for the treatment of asthma and chronic obstructive pulmonary disease.
*The compound is unstable in solutions, freshly prepared is recommended
 |
Source | J Pharmacol Exp Ther (2011). Figure 3. GSK256066 |
| Method | i.v. | |
| Cell Lines | mice | |
| Concentrations | 10 μg/kg | |
| Incubation Time | 6 h | |
| Results | GSK256066 and FP inhibited the increase in eosinophil number in the BAL in a dose-dependent fashion |
| Cell Experiment | |
|---|---|
| Cell lines | PBMCs cells line |
| Preparation method | Compound Preparation for In Vitro Assays. Dilution series for pIC50 determinations generally comprised eight successive 3-fold dilutions in DMSO. Low-volume additions (0.5-2.0 μl) to assays were carried out using a Biomek Fx liquid-handling robot (Beckman Coulter, Fullerton, CA).Percentages of inhibition values were generated relative to uninhibited controls. Values for pIC50 were determined from concentration-response curves by nonlinear least-squares curve fitting, in general using a four-parameter logistic equation in Activity Base (IDBS, Guildford, Surrey, UK). |
| Concentrations | 0~10 μM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | LPS-induced pulmonary neutrophilia in rats model |
| Formulation | 0.2% Tween 80 in normal saline |
| Dosages | 0.1-100 μg/kg |
| Administration | intratracheally |
| Molecular Weight | 518.58 |
| Formula | C27H26N4O5S |
| CAS Number | 801312-28-7 |
| Solubility (25°C) | DMSO 12 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PDE Products |
|---|
| MR-L2
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM. |
| MMPX
MMPX is a potent PDE1 inhibitor. |
| T-0156
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. |
| TPN171
TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH). |
| Mesopram
Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
